You are here

Shire

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

Flag link:

Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3

Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3

Fierce Biotech

Certa Therapeutics

autoimmune disease

clinical trials

Flag link:

Takeda shunts jewel of Shire takeover to new spinoff Oak Hill

Takeda shunts jewel of Shire takeover to new spinoff Oak Hill

Fierce Biotech

Flag link:

FDA offers support for Takeda's potential cytomegalovirus drug ahead of adcomm

FDA offers support for Takeda's potential cytomegalovirus drug ahead of adcomm

Endpoints

post-transplant cytomegalovirus

Flag link:

Former Shire asset becomes Mirum’s first FDA-approved rare disease drug

Former Shire asset becomes Mirum’s first FDA-approved rare disease drug

MedCity News

Mirum Pharmaceuticals

Alagille syndrome

Flag link:

AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit

AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit

Fierce Pharma

Flag link:

Takeda still on the hook for €398M tax linked to distant AbbVie-Shire breakup fee

Takeda still on the hook for €398M tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

Flag link:

Takeda tees up priority review for storied CMV drug from its $62B Shire buyout

Takeda tees up priority review for storied CMV drug from its $62B Shire buyout

Endpoints

Flag link:

Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown

Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown

Fierce Pharma

early retirement

Flag link:

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Endpoints

Flag link:

Takeda continues post-Shire selloff, inching closer to $10B goal

Takeda continues post-Shire selloff, inching closer to $10B goal

Endpoints

Flag link:

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Endpoints

Flag link:

Takeda posts surprise profit a year after Shire mega-merger

Takeda posts surprise profit a year after Shire mega-merger

Pharmaforum

Flag link:

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Endpoints

Flag link:

Takeda Pharmaceutical Raises Its Profit Outlook

Takeda Pharmaceutical Raises Its Profit Outlook

Motley Fool

Flag link:

Takeda puts Shire biologics plant with 200 employees on the block

Takeda puts Shire biologics plant with 200 employees on the block

Fierce Pharma

drug manufacturing

Flag link:

Takeda pares down products and jobs, revives Genzyme building plans

Takeda pares down products and jobs, revives Genzyme building plans

Bizjournals

Flag link:

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Pharmaforum

Flag link:

Takeda breaks into top 20 largest pharmas with Shire merger

Takeda breaks into top 20 largest pharmas with Shire merger

Pharmaforum

Flag link:

Pages